The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Use of metformin to treat pregnant women with polycystic ovary syndrome (PregMet2): a randomised, double-blind, placebo-controlled trial
Open accessAbstract
Background Women with polycystic ovary syndrome (PCOS) have an increased risk of pregnancy complications. Epi-analysis of two previous randomised controlled trials that compared metformin with placebo during pregnancy in women with PCOS showed a significant reduction in late miscarriages and preterm births in the metformin group. The aim of this third randomised trial (PregMet2) was to test the hypothesis that metformin prevents late miscarriage and preterm birth in women with PCOS.Methods PregMet2 was a randomised, placebo-controlled, double-blind, multicentre trial done at 14 hospitals in Norway, Sweden, and Iceland. Singleton pregnant women with PCOS aged 18-45 years were eligible for inclusion. After receiving information about the study at their first antenatal visit or from the internet, women signed up individually to participate in the study. Participants were randomly assigned (1:1) to receive metformin or placebo by computer-generated random numbers. Randomisation was in blocks of ten for each country and centre; the first block had a random size between one and ten to assure masking. Participants were assigned to receive oral metformin 500 mg twice daily or placebo during the first week of treatment, which increased to 1000 mg twice daily or placebo from week 2 until delivery. Placebo tablets and metformin tablets were identical and participants and study personnel were masked to treatment allocation. The primary outcome was the composite incidence of late miscarriage (between week 13 and week 22 and 6 days) and preterm birth (between week 23 and week 36 and 6 days), analysed in the intention-to-treat population. Secondary endpoints included the incidence of gestational diabetes, preeclampsia, pregnancy-induced hypertension, and admission of the neonate to the neonatal intensive care unit. We also did a post-hoc individual participant data analysis of pregnancy outcomes, pooling data from the two previous trials with the present study. The study was registered with ClinicalTrials.gov, number NCT01587378, and EudraCT, number 2011-002203-15.Findings The study took place between Oct 19, 2012, and Sept 1, 2017. We randomly assigned 487 women to metformin (n=244) or placebo (n=243). In the intention-to-treat analysis, our composite primary outcome of late miscarriage and preterm birth occurred in 12 (5%) of 238 women in the metformin group and 23 (10%) of 240 women in the placebo group (odds ratio [OR] 0·50, 95% CI 0·22-1·08; p=0·08). We found no significant differences for our secondary endpoints, including incidence of gestational diabetes (60 [25%] of 238 women in the metformin group vs 57 [24%] of 240 women in the placebo group; OR 1·09, 95% CI 0·69-1·66; p=0·75). We noted no substantial between-group differences in serious adverse events in either mothers or offspring, and no serious adverse events were considered drug-related by principal investigators. In the post-hoc pooled analysis of individual participant data from the present trial and two previous trials, 18 (5%) of 397 women had late miscarriage or preterm delivery in the metformin group compared with 40 (10%) of 399 women in the placebo group (OR 0·43, 95% CI 0·23-0·79; p=0·004).Interpretation In pregnant women with PCOS, metformin treatment from the late first trimester until delivery might reduce the risk of late miscarriage and preterm birth, but does not prevent gestational diabetes.Funding Research Council of Norway, Novo Nordisk Foundation, St Olav's University Hospital, and Norwegian University of Science and Technology.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
(2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2003.10.004 · Cited by 9,050
Men at risk: occupation and male infertility
Claman, P. (2004) · Fertility and Sterility · doi:10.1016/s0015-0282(03)01188-9 · Cited by 2,387
Cellular and molecular mechanisms of metformin: an overview
Viollet, B., Guigas, B., Garcia, N. S., Leclerc, J., Foretz, M., & Andreelli, F. (2012) · Clinical Science · doi:10.1042/cs20110386 · Cited by 1,720
Metformin: from mechanisms of action to therapies
Foretz, M., Guigas, B., Bertrand, L., Pollak, M., & Viollet, B. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.09.018 · Cited by 1,501
Anti-inflammatory effects of metformin irrespective of diabetes status
Cameron, A. R., Morrison, V. L., Levin, D., Mohan, M., Forteath, C., Beall, C., McNeilly, A. D., Balfour, D. J. K., Savinko, T., Wong, A. K. F., et al. (2016) · Circulation Research · doi:10.1161/circresaha.116.308445 · Cited by 704
Diagnostic Criteria and Classification of Hyperglycaemia First Detected in Pregnancy
Agarwal, M., Boulvain, M., Coetzee, E. J., Colagiuri, S., Falavigna, M., Hod, M., Meltzer, S. J., Metzger, B. E., Omori, Y., Rasa, I., et al. (2013) · Cited by 536
Metformin versus placebo in obese pregnant women without diabetes mellitus
Syngelaki, A., Nicolaides, K. H., Balani, J., Hyer, S., Akolekar, R., Kotecha, R., Pastides, A., & Shehata, H. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1509819 · Cited by 394
Preterm birth time trends in Europe: a study of 19 countries
Zeitlin, J., Szamotulska, K., Drewniak, N., Mohangoo, A., Chalmers, J., Sakkeus, L., Irgens, L., Gatt, M., Gissler, M., Blondel, B., et al. (2013) · BJOG: An International Journal of Obstetrics & Gynaecology · doi:10.1111/1471-0528.12281 · Cited by 328
Roos, N., Kieler, H., Sahlin, L., Ekman-Ordeberg, G., Falconer, H., & Stephansson, O. (2011) · BMJ · doi:10.1136/bmj.d6309 · Cited by 316
Vanky, E., Stridsklev, S., Heimstad, R., Romundstad, P., Skogøy, K., Kleggetveit, O., Hjelle, S., von Brandis, P., Eikeland, T., Flo, K., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0853 · Cited by 315
Self-citation
Cited by
Endometrial function in women with polycystic ovary syndrome: a comprehensive review
Palomba, S., Piltonen, T. T., & Giudice, L. C. (2021) · Human Reproduction Update · doi:10.1093/humupd/dmaa051 · Cited by 372
Metformin in aging and aging-related diseases: clinical applications and relevant mechanisms
Chen, S., Gan, D., Lin, S., Zhong, Y., Chen, M., Zou, X., Shao, Z., & Xiao, G. (2022) · Theranostics · doi:10.7150/thno.71360 · Cited by 190
Recurrent miscarriage: evidence to accelerate action
Coomarasamy, A., Dhillon-Smith, R. K., Papadopoulou, A., Al-Memar, M., Brewin, J., Abrahams, V. M., Maheshwari, A., Christiansen, O. B., Stephenson, M. D., Goddijn, M., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00681-4 · Cited by 180
Systemic and ovarian inflammation in women with polycystic ovary syndrome
Zhai, Y., & Pang, Y. (2022) · Journal of Reproductive Immunology · doi:10.1016/j.jri.2022.103628 · Cited by 133
César, M. J. P., Molina‐Vega, M., Suárez-Arana, M., González‐Mesa, E., Sola-Moyano, A. P., Roldan-López, R., Romero-Narbona, F., Olveira, G., Tinahones, F. J., & González‐Romero, S. (2021) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2021.04.229 · Cited by 106
Metadata
- Authors
- Løvvik, T. S., Carlsen, S. M., Salvesen, Ø., Steffensen, B., Bixo, M., Gómez-Real, F., Lønnebotn, M., Hestvold, K. V., Zabielska, R., Hirschberg, A. L., Trouva, A., Thorarinsdottir, S., Hjelle, S., Berg, A. H., Andræ, F., Poromaa, I. S., Mohlin, J., Underdal, M., & Vanky, E.
- Affiliations
- Norwegian University of Science and Technology (NO)
- National University Hospital of Iceland (IS)
- Umeå University (SE)
- Haukeland University Hospital (NO)
- Vestre Viken Hospital Trust (NO)
- Sykehuset i Vestfold (NO)
- Karolinska University Hospital (SE)
- Uppsala University (SE)
- Telemark Hospital (NO)
- Ålesund Hospital (NO)
- Innlandet Hospital Trust (NO)
- Nordland Hospital Trust (NO)
- Stockholm South General Hospital (SE)
- Corresponding author
- Løvvik, Tone S
- ORCID
- Venue
- The Lancet Diabetes & Endocrinology
- Publisher
- Elsevier BV
- Published
- 2019-04
- Volume
- 7
- Issue
- 4
- Pages
- 256-266
- ISSN
- 2213-8587 (ISSN-L)
- OpenAlex
- W2916534006
- Cited by
- 176
- References
- 33
- Citations by year
- 2026: 22 · 2025: 17 · 2024: 22 · 2023: 31 · 2022: 31 · 2021: 27 · 2020: 17 · 2019: 9
- FWCI
- 20.08
- Type
- journal article
- Language
- en
- Open access
- green
- urn.kb.se
- Licence
- other-oa
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Locations
- The Lancet Diabetes & Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- DiVA at Umeå University (Umeå University) (submittedVersion, other-oa)
- Hirsla (Landspítali University Hospital) (submittedVersion)
- Funders
- Novo Nordisk Fonden
- St. Olavs Hospital Universitetssykehuset i Trondheim
- Norges Teknisk-Naturvitenskapelige Universitet
- Norges Forskningsråd
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Obstetrics and Gynecology › Gestational Diabetes Research and Management
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
- Keywords
- polycystic ovary syndrome, pregnancy, late miscarriage, preterm birth, gestational diabetes mellitus, preeclampsia, gestational hypertension, neonatal intensive care admission, individual patient data meta-analysis, pregnancy outcomes
- MeSH terms
- Abortion, Spontaneous, Adolescent, Adult, Blood Glucose, Double-Blind Method, Female, Follow-Up Studies, Humans, Hypoglycemic Agents, Iceland, Infant, Newborn, Metformin, Middle Aged, Norway, Polycystic Ovary Syndrome, Pregnancy, Pregnancy Complications, Prognosis, Sweden, Biomarkers, Incidence, Diabetes, Gestational, Premature Birth, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Use of metformin to treat pregnant women with polycystic ovary syndrome (PregMet2): a randomised, double-blind, placebo-controlled trial. https://app.cochat.ai/papers/10.1016/s2213-8587(19)30002-6
- The paper
- Løvvik, T. S., Carlsen, S. M., Salvesen, Ø., Steffensen, B., Bixo, M., Gómez-Real, F., Lønnebotn, M., Hestvold, K. V., Zabielska, R., Hirschberg, A. L., Trouva, A., Thorarinsdottir, S., Hjelle, S., Berg, A. H., Andræ, F., Poromaa, I. S., Mohlin, J., Underdal, M., & Vanky, E. (2019). Use of metformin to treat pregnant women with polycystic ovary syndrome (PregMet2): a randomised, double-blind, placebo-controlled trial. The Lancet Diabetes & Endocrinology. https://doi.org/10.1016/s2213-8587(19)30002-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.